<DOC>
	<DOCNO>NCT00486174</DOCNO>
	<brief_summary>The purpose study investigate whether addition Methylene Blue standard treatment septic shock reduce vasopressor requirement</brief_summary>
	<brief_title>Methylene Blue Sepsis : A Randomized Controlled Trial</brief_title>
	<detailed_description>The management severe infection , sepsis septic shock serious problem facing physician . Septic shock kill 10,000 Canadians every year . It common cause death intensive unit rate sepsis septic shock continue increase annually . Septic shock complex interaction pathologic vasodilation , relative absolute hypovolemia , myocardial depression , alter microvascular function result systemic inflammatory response infection . After restoration circulating volume , many patient continue suffer maldistribution blood flow . Current hypothesis suggest global indicator hypoperfusion ( serum lactate , hypotension , decrease oxygen delivery ) represent average area normal increase blood flow area blood flow decrease . These under-perfused area become hypoxic . The result tissue damage lead inflammation maldistribution , perpetuate vicious cycle progress death . Vasopressive agent use attempt maintain mean arterial blood pressure restore perfusion , agent work globally , potentially worsen blood flow under-perfused area . As well , many vasopressor deleterious side effect metabolic endocrine function , change regional blood flow . The microvascular change mediate primarily nitric oxide ( NO ) . Baseline level nitric oxide produce constitutive Nitric Oxide Synthase ( cNOS ) , NO level measure nano-molar range . Inflammatory mediator cause increase production inducible Nitric Oxide Synthase ( iNOS ) lead NO level measure micro-molar range . Suppression nitric oxide production use non-specific NOS inhibitor discourage result . Methylene Blue selective iNOS inhibitor . The purpose pilot study confirm safety demonstrate sign benefit use methylene blue sepsis . In particular , study examine whether addition methylene blue standard early goal direct therapy sepsis reduce vasopressor requirement .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>First presentation sepsis syndrome : clinical evidence infection Systemic Inflammatory Response Syndrome ( SIRS ) define two : Temperature &gt; 38°C &lt; 36°C , Heart rate &gt; 90 beat per minute , One respiratory rate &gt; 20 , hyperventilation PaCO2 &lt; 32 mm Hg , require mechanical ventilation , One white blood cell &gt; 12,000 X 109 /L white blood cell &lt; 4000 X 109 /L immature neutrophil &gt; 10 % . Undergoing early goal direct therapy mean arterial blood pressure ( MAP ) &lt; 65 mmHg despite fluid resuscitation CVP &gt; 10mmHg . Able provide inform consent per institutional standard . To receive first dose study drug within six hour first record hypotension ( MAP &lt; 65mmHg ) . Age &lt; 18 year . Undergoing palliation . Not expect survive 48 hour . Resuscitated vital sign absent arrest . Ongoing dialysis . Anuric creatinine &gt; 300 μmol/L . Pregnant . Patient family history glucose6phosphate dehydrogenase deficiency . Allergic methylene blue , phenothiazine , thiazide diuretic , food dye . Patient mass &gt; 150 kg . Demonstrated Pulmonary Hypertension ( Mean Pulmonary Artery Pressure &gt; 25 mmHg Swan Ganz Catheter Echo demonstrate Right Ventricular Systolic Pressure &gt; 40 mmHg ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Sepsis</keyword>
	<keyword>Methylene Blue</keyword>
	<keyword>Norepinephrine</keyword>
</DOC>